Wedelolactone ameliorates synovial inflammation and cardiac complications in a murine model of collagen-induced arthritis by inhibiting NF-κB/NLRP3 inflammasome activation
Abstract
Introduction. Rheumatoid arthritis (RA) is an autoimmune disorder associated with joint damage and attendant cardiovascular complications. Wedelolactone (Wed), derived from Eclipta alba, possesses anti-inflammatory activity. Whether Wed regulates RA inflammation and related heart damage remains unknown.
Material and methods. A murine model of collagen-induced arthritis (CIA) was well-established by two subcutaneous injections of type II collagen (days 0 and 21). Wed was then administered via intraperitoneal injection every other day from day 28 to day 48. Joint swelling was monitored and paw thickness was calculated. Histopathological changes in synovial tissues or ankle cartilage were evaluated by hematoxylin and eosin (H&E) and Safranin O-Fast Green staining. The concentrations of inflammatory factors in serum and synovial tissues were detected by ELISA. The qRT-PCR, Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) were performed to assess receptor activator of nuclear factor kappa ligand (RANKL), matrix metalloprotease (MMP)-3, NLRP3, caspase-1 (pro- and cleaved forms), p-p65, IκBα, p-IκBα, p65, αsmooth-actin 2 (ACTA2), collagen type I and E-cadherin expression. H&E and Masson staining were used to assess the pathological alterations in the heart.
Results. Treatment with Wed ameliorated ankle joint swelling and cartilage degradation. Wed decreased the infiltration of inflammatory cells, the release of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, and IL-18), and the expression of RANKL and MMP-3 in serum and synovial tissues of CIA mice. Moreover, Wed increased the expression of NLRP3 and cleaved-caspase-1 in the synovium, leading to IL-1β and IL-18 secretion. Nuclear factor-kappaB (NF-κB) activation in synovial tissues was suppressed by Wed, as manifested by reduced phosphorylation of p65 and IκBα and nuclear translocation of p65. Furthermore, Wed reduced in CIA mice heart weight/body weight ratio and dampened cardiac inflammation and fibrosis that was accompanied at the mRNA level by down-regulation of ACTA2 and collagen I and up-regulation of E-cadherin.
Conclusions. These findings suggested that Wed attenuated synovial inflammation and joint damage in a mouse model of RA via inhibiting NF-κB/NLRP3 inflammasome activation, and ameliorated RA-induced cardiac complications.
Keywords: mousewedelolactonecollagen-induced arthritisNLRP3NF-κBcardiac fibrosis
References
- Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010; 376(9746): 1094–1108.
- Jang S, Kwon EJ, Lee JJ. Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int J Mol Sci. 2022; 23(2): 905.
- Pandolfi F, Franza L, Carusi V, et al. Interleukin-6 in rheumatoid arthritis. Int J Mol Sci. 2020; 21(15): 5238.
- Yuan F, Quan Ld, Cui L, et al. Development of macromolecular prodrug for rheumatoid arthritis. Adv Drug Deliv Rev. 2012; 64(12): 1205–1219.
- Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012; 51 Suppl 5: v3–11.
- Dessein PH, Norton GR, Woodiwiss AJ, et al. Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol. 2007; 34(5): 943–951.
- Yuan F, Chen J, Sun Pp, et al. Wedelolactone inhibits LPS-induced pro-inflammation via NF-kappaB pathway in RAW 264.7 cells. J Biomed Sci. 2013; 20: 84.
- Ali F, Khan BA, Sultana S. Wedelolactone mitigates UVB induced oxidative stress, inflammation and early tumor promotion events in murine skin: plausible role of NFkB pathway. Eur J Pharmacol. 2016; 786: 253–264.
- Xia Y, Chen J, Cao Y, et al. Wedelolactone exhibits anti-fibrotic effects on human hepatic stellate cell line LX-2. Eur J Pharmacol. 2013; 714(1-3): 105–111.
- Fan R, Sui J, Dong X, et al. Wedelolactone alleviates acute pancreatitis and associated lung injury via GPX4 mediated suppression of pyroptosis and ferroptosis. Free Radic Biol Med. 2021; 173: 29–40.
- Luo Q, Ding J, Zhu L, et al. Hepatoprotective effect of wedelolactone against concanavalin a-induced liver injury in mice. Am J Chin Med. 2018; 46(4): 819–833.
- Pan H, Lin Y, Dou J, et al. Wedelolactone facilitates Ser/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis. Cell Prolif. 2020; 53(9): e12868.
- Melo PA, Pinheiro DA, Ricardo HD, et al. Ability of a synthetic coumestan to antagonize Bothrops snake venom activities. Toxicon. 2010; 55(2-3): 488–496.
- Kolly L, Busso N, Palmer G, et al. Expression and function of the NALP3 inflammasome in rheumatoid synovium. Immunology. 2010; 129(2): 178–185.
- Cheng L, Liang X, Qian L, et al. NLRP3 gene polymorphisms and expression in rheumatoid arthritis. Exp Ther Med. 2021; 22(4): 1110.
- Wu XY, Li KT, Yang HX, et al. Complement C1q synergizes with PTX3 in promoting NLRP3 inflammasome over-activation and pyroptosis in rheumatoid arthritis. J Autoimmun. 2020; 106: 102336.
- Guo C, Fu R, Wang S, et al. NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis. Clin Exp Immunol. 2018; 194(2): 231–243.
- Holmdahl R, Bockermann R, Bäcklund J, et al. The molecular pathogenesis of collagen-induced arthritis in mice--a model for rheumatoid arthritis. Ageing Res Rev. 2002; 1(1): 135–147.
- Wei W, Ding M, Zhou K, et al. Protective effects of wedelolactone on dextran sodium sulfate induced murine colitis partly through inhibiting the NLRP3 inflammasome activation via AMPK signaling. Biomed Pharmacother. 2017; 94: 27–36.
- Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007; 2(5): 1269–1275.
- van Loo G, Beyaert R. Negative regulation of NF-κB and its involvement in rheumatoid arthritis. Arthritis Res Ther. 2011; 13(3): 221.
- Momohara S, Okamoto H, Iwamoto T, et al. High CCL18/PARC expression in articular cartilage and synovial tissue of patients with rheumatoid arthritis. J Rheumatol. 2007; 34(2): 266–271.
- Smolen J, Aletaha D, McInnes I. Rheumatoid arthritis. Lancet. 2016; 388(10055): 2023–2038.
- Tincani A, Andreoli L, Bazzani C, et al. Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev. 2007; 7(1): 1–7.
- Cheng M, Lin J, Li C, et al. Wedelolactone suppresses IL-1β maturation and neutrophil infiltration in Aspergillus fumigatus keratitis. Int Immunopharmacol. 2019; 73: 17–22.
- Prakash T, Janadri S. Anti-inflammatory effect of wedelolactone on DSS induced colitis in rats: IL-6/STAT3 signaling pathway. J Ayurveda Integr Med. 2022 [Epub ahead of print]: 100544.
- Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford). 2008; 47(11): 1635–1640.
- Fujii Y, Inoue H, Arai Y, et al. Treadmill running in established phase arthritis inhibits joint destruction in rat rheumatoid arthritis models. Int J Mol Sci. 2019; 20(20).
- Papadaki M, Rinotas V, Violitzi F, et al. New insights for RANKL as a proinflammatory modulator in modeled inflammatory arthritis. Front Immunol. 2019; 10: 97.
- Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006; 12(1): 17–25.
- Tanaka S, Tanaka Y, et al. RANKL as a therapeutic target for bone destruction in rheumatoid arthritis. J Bone Miner Metab. 2021; 39(1): 106–112.
- Sun X, Feng X, Tan W, et al. Adiponectin exacerbates collagen-induced arthritis via enhancing Th17 response and prompting RANKL expression. Sci Rep. 2015; 5: 11296.
- Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006; 11: 529–543.
- Araki Y, Mimura T. Matrix metalloproteinase gene activation resulting from disordred epigenetic mechanisms in rheumatoid arthritis. Int J Mol Sci. 2017; 18(5): 905.
- Qin Yi, Cai ML, Jin HZ, et al. Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways. Ann Rheum Dis. 2022 [Epub ahead of print].
- Du F, Lü Lj, Teng Jl, et al. T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro. Int Immunopharmacol. 2012; 13(1): 54–60.
- Tetlow LC, Lees M, Ogata Y, et al. Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int. 1993; 13(2): 53–59.
- Ma JD, Zhou JJ, Zheng DH, et al. Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediators Inflamm. 2014; 2014: 179284.
- Li Z, Guo J, Bi L. Role of the NLRP3 inflammasome in autoimmune diseases. Biomed Pharmacother. 2020; 130: 110542.
- Jäger E, Murthy S, Schmidt C, et al. Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis. Nat Commun. 2020; 11(1): 4243.
- Wang H, Wang Z, Wang L, et al. IL-6 promotes collagen-induced arthritis by activating the NLRP3 inflammasome through the cathepsin B/S100A9-mediated pathway. Int Immunopharmacol. 2020; 88: 106985.
- Yin H, Liu Na, Sigdel KR, et al. Role of NLRP3 inflammasome in rheumatoid arthritis. Front Immunol. 2022; 13: 931690.
- Unterberger S, Davies KA, Rambhatla SB, et al. Contribution of toll-like receptors and the NLRP3 inflammasome in rheumatoid arthritis pathophysiology. Immunotargets Ther. 2021; 10: 285–298.
- Deng Y, Luo H, Shu J, et al. Pien Tze Huang alleviate the joint inflammation in collagen-induced arthritis mice. Chin Med. 2020; 15: 30.
- Tenshin H, Teramachi J, Ashtar M, et al. TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression. Clin Transl Immunology. 2022; 11(1): e1371.
- Zhu MM, Wang L, Yang D, et al. Wedelolactone alleviates doxorubicin-induced inflammation and oxidative stress damage of podocytes by IκK/IκB/NF-κB pathway. Biomed Pharmacother. 2019; 117: 109088.
- Liu H, Zhu Y, Gao Y, et al. NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis. Cell Death Dis. 2020; 11(2): 129.
- Li J, Tang RS, Shi Z, et al. Nuclear factor-κB in rheumatoid arthritis. Int J Rheum Dis. 2020; 23(12): 1627–1635.
- He J, Zheng S. NF-κB phosphorylation inhibition prevents articular cartilage degradation in osteoarthritis rats via 2-aminoquinoline. Med Sci Monit. 2020; 26: e920346.
- Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004; 10(6): 617–624.
- Wang Z, Huang W, Ren F, et al. Characteristics of ang-(1-7)/mas-mediated amelioration of joint inflammation and cardiac complications in mice with collagen-induced arthritis. Front Immunol. 2021; 12: 655614.
- Haneklaus M, O'Neill LAJ. NLRP3 at the interface of metabolism and inflammation. Immunol Rev. 2015; 265(1): 53–62.
- Swanson KV, Deng M, Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019; 19(8): 477–489.
- England BR, Thiele GM, Anderson DR, et al. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018; 361: k1036.
